{"GPL19915": [{"GSM1638590": [{"title": "OV202SH2_1"}, {"type": "RNA"}, {"source_name_ch1": "primary OV202 cell line"}, {"characteristics_ch1": "cell line: OV202;\tcell type: ovarian carcinoma;\tgroup: Sh2"}]}, {"GSM1638591": [{"title": "OV202SH2_2"}, {"type": "RNA"}, {"source_name_ch1": "primary OV202 cell line"}, {"characteristics_ch1": "cell line: OV202;\tcell type: ovarian carcinoma;\tgroup: Sh2"}]}, {"GSM1638592": [{"title": "OV202SH2_3"}, {"type": "RNA"}, {"source_name_ch1": "primary OV202 cell line"}, {"characteristics_ch1": "cell line: OV202;\tcell type: ovarian carcinoma;\tgroup: Sh2"}]}, {"GSM1638593": [{"title": "OV202NTC_1"}, {"type": "RNA"}, {"source_name_ch1": "primary OV202 cell line"}, {"characteristics_ch1": "cell line: OV202;\tcell type: ovarian carcinoma;\tgroup: NTC"}]}, {"GSM1638594": [{"title": "OV202NTC_2"}, {"type": "RNA"}, {"source_name_ch1": "primary OV202 cell line"}, {"characteristics_ch1": "cell line: OV202;\tcell type: ovarian carcinoma;\tgroup: NTC"}]}, {"GSM1638595": [{"title": "OV202NTC_3"}, {"type": "RNA"}, {"source_name_ch1": "primary OV202 cell line"}, {"characteristics_ch1": "cell line: OV202;\tcell type: ovarian carcinoma;\tgroup: NTC"}]}, {"GSM1638596": [{"title": "OV202SH1_1"}, {"type": "RNA"}, {"source_name_ch1": "primary OV202 cell line"}, {"characteristics_ch1": "cell line: OV202;\tcell type: ovarian carcinoma;\tgroup: Sh1"}]}, {"GSM1638597": [{"title": "OV202SH1_2"}, {"type": "RNA"}, {"source_name_ch1": "primary OV202 cell line"}, {"characteristics_ch1": "cell line: OV202;\tcell type: ovarian carcinoma;\tgroup: Sh1"}]}, {"GSM1638598": [{"title": "OV202SH1_3"}, {"type": "RNA"}, {"source_name_ch1": "primary OV202 cell line"}, {"characteristics_ch1": "cell line: OV202;\tcell type: ovarian carcinoma;\tgroup: Sh1"}]}, {"GSM1645562": [{"title": "Normal CD3+/CD8+ 1"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: none;\ttreatment: none;\tadditional treatment: none"}]}, {"GSM1645563": [{"title": "Normal CD3+/CD8+ 2"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: none;\ttreatment: none;\tadditional treatment: none"}]}, {"GSM1645564": [{"title": "Normal CD3+/CD8+ 3"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: none;\ttreatment: none;\tadditional treatment: none"}]}, {"GSM1645565": [{"title": "Normal CD3+/CD8+ 4"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: none;\ttreatment: none;\tadditional treatment: none"}]}, {"GSM1645566": [{"title": "T-PLL pre 1"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: pre-treatment;\ttreatment: alemtuzumab, cladribine;\tadditional treatment: none"}]}, {"GSM1645567": [{"title": "T-PLL pre 2"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: pre-treatment;\ttreatment: alemtuzumab, cladribine;\tadditional treatment: vorinostat"}]}, {"GSM1645568": [{"title": "T-PLL pre 3"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: pre-treatment;\ttreatment: alemtuzumab, cladribine;\tadditional treatment: none"}]}, {"GSM1645569": [{"title": "T-PLL pre 4"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: pre-treatment;\ttreatment: alemtuzumab, cladribine;\tadditional treatment: none"}]}, {"GSM1645570": [{"title": "T-PLL post 1"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: 3 days post-treatment;\ttreatment: alemtuzumab, cladribine;\tadditional treatment: none"}]}, {"GSM1645571": [{"title": "T-PLL post 2"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: 3 days post-treatment;\ttreatment: alemtuzumab, cladribine;\tadditional treatment: vorinostat"}]}, {"GSM1645572": [{"title": "T-PLL post 3"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: 3 days post-treatment;\ttreatment: alemtuzumab, cladribine;\tadditional treatment: none"}]}, {"GSM1645573": [{"title": "T-PLL post 4"}, {"type": "RNA"}, {"source_name_ch1": "PBMC"}, {"characteristics_ch1": "treatment status: 3 days post-treatment;\ttreatment: alemtuzumab, cladribine;\tadditional treatment: none"}]}]}